Patent: 9,345,677
✉ Email this page to a colleague
Summary for Patent: 9,345,677
Title: | Compositions, methods and kits relating to HER-2 cleavage |
Abstract: | The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated. |
Inventor(s): | Friedman; Steven M. (West Chester, PA), Scherle; Peggy A. (Media, PA), Liu; Xiangdong (Metchuen, NJ), Vaddi; Krishna (Hockessin, DE), Fridman; Jordan S. (Newark, DE) |
Assignee: | Incyte Corporation (Wilmington, DE) Incyte Holdings Corporation (Wilmington, DE) |
Application Number: | 13/336,587 |
Patent Claims: | see list of patent claims |
Details for Patent 9,345,677
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2023-04-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2023-04-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2023-04-04 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2023-04-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |